Cancer gene therapy: Lessons learned from experiences with chemotherapy

Molecular Therapy

Volumn 7, Issue 6, 2003, Pages 717-719

  Morris, John C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALKYLATING AGENT; ANGIOSTATIN; CISPLATIN; CONNEXIN 26; CYTOTOXIC AGENT; DOCETAXEL; FLUOROURACIL; FOLIC ACID ANTAGONIST; HYDROXYUREA; ONYX 015; PROTEIN P53; TAXANE DERIVATIVE; THYMIDYLATE SYNTHASE INHIBITOR; TOPOTECAN; TRANSCRIPTION FACTOR E2F; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VIRUS PROTEIN;

ANTINEOPLASTIC ACTIVITY; CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CYTOTOXICITY; DOSE RESPONSE; DRUG POTENTIATION; ENDOTHELIUM CELL; HUMAN; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; NONHUMAN; SHORT SURVEY; TUMOR VASCULARIZATION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ADENOVIRIDAE;

EID: 0038489123     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1525-0016(03)00156-4     Document Type: Review

References (39)

1. DeVita, V. T. (1978). The evolution of therapeutic research in cancer. N. Engl. J. Med. 298: 907-910.
2. Nathanson, L., et al. (1969). Concurrent combination chemotherapy of human solid tumors: experience with a three-drug regimen and a review of the literature. Cancer Res. 29: 419-425.
3. Chu, E., and DeVita, V. T. (2001). Principles of management: chemotherapy. In: Cancer: Principles and Practice of Oncology. 6th Ed. (V. T. DeVita, S. Heilman and S. A. Rosenberg, eds.) pp. 289-306. J. B. Lippincott Co., Philadelphia.
4. Lonning, P. E. (2003). Study of suboptimum treatment response: lessons from breast cancer. Lancet Oncol. 4: 177-185.
5. Robinson, L. A., Wagner, H., and Ruckdeschel J. C. (2003). Treatment of Stage IIIA non-small cell lung cancer. Chest 123(1 Suppl): 202S-220S.
6. Dillman, R. O., et al. (1996). Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J. Natl Cancer Inst. 88: 1210-1215.
7. Calais, G., et al. (1999). Randomized trial of radiation therapy versus concomitant chemotherapy with radiation therapy for advanced-stage oropharynx carcinoma. J. Natl. Cancer Inst. 91: 2081-2086.
8. Rose, P. G., et al. (1999). Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N. Engl. J. Med. 340: 1144-1153.
9. Chou, T. C. (1991). The median-effect principle and the combination index for quantitation of synergy and antagonism. In: Synergy and Antagonism in Chemotherapy. (T. C. Chou and D. C. Rideout, eds.) pp. 61-102. Academic Press, New York.
10. Chou, T. C., Motzer, R. J., Tong, Y., and Bosl, G. J. (1994). Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J. Natl. Cancer Instit. 86: 1517-1524.
11. Galaup, A., et al. (2003). Combined effects of dcetaxel and angiostatin gene therapy in a prostate tumor model. Mol. Ther., this issue.
12. Folkman, J. (1971). Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285: 1182-1186.
13. Perez-Atayde, A. R., et al. (1997). Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am. J. Pathol. 150: 815-821.
14. Folkman, J., Cole, P., and Zimmerman, S. (1966). Tumor behavior in isolated perfused organs: in vitro growth and metastases of biopsy material in rabbit thyroid and canine intestinal segment. Ann. Surg. 164: 491-502.
15. Hanahan, D., and Folkman, J. (1996). Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364.
16. Cao, Y., et al. (1996). Kringle domains of human angiostatin: characterization of the anti-proliferative activity on endothelial cells. J. Biol. Chem. 271: 29461-29467.
17. O'Reilly, M. S., et al. (1994). Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79: 315-328.
18. O'Reilly, M. S., Holmgren, L., Chen, C., and Folkman, J. (1996). Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat. Med. 2: 689-692.
19. Liotta, L. A., Steeg, P. S., Stetler-Stevenson, W. G. (1991). Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64: 327-336.
20. Scappaticci, F. A. (2002). Mechanisms and future directions for angiogenesis-based cancer therapies. J. Clin. Oncol. 20: 3906-3927.
21. Bach, L. A., Bentzen, S. M., Alsner, J., and Christiansen, F. B. (2001 ). An evolutionary-game model of tumour-cell interactions: possible relevance to gene therapy. Eur. J. Cancer 37: 2116-2120.
22. Miller, K. D., Sweeney, C. J. and Sledge, G. W. (2001). Redefining the target: chemotherapeutics as antiangiogenics. J. Clin. Oncol. 19: 1195-1206.
23. Burke, P. A., and DeNardo, S. J. (2001). Antiangiogenic agents and their promising potential in combined therapy. Crit. Rev. Oncol. Hematol. 39: 155-171.
24. Gorski, D. H., et al. (1998). Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin. Cancer Res. 58: 5686-5689.
25. Aghi, M., et al. (1998). Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine deaminase gene therapies. J. Natl. Cancer Inst. 90: 370-380.
26. Wildner, O., Blaese, R. M., and Candotti, F. (1999). Enzyme prodrug gene therapy: synergistic use of the herpes simplex virus-cellular thymidine kinase/ganciclovir system and thymidylate synthase inhibitors for the treatment of colon cancer. Cancer Res. 59: 5233-5238.
27. Freytag, S. O., et al. (2002). Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res. 2: 4968-4976.
28. Herman, J. R., et al. (1999). In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial. Hum. Gene Ther. 10: 1239-1249.
29. Boucher, P. D., Ostruszka, L. J., and Shewach, D. S. (2000). Synergistic enhancement of herpes simplex virus thymidine kinase/ganciclovir-mediated cytoxicity by hydroxyurea. Cancer Res. 60: 1631-1636.
30. Wildner, O., Blaese, R. M., Morris, J. C. (1999). Synergy between the herpes simplex virus tk/ganciclovir prodrug suicide system and the topoisomerase I inhibitor topotecan. Hum. Gene Ther. 10: 2679-2687.
31. Tong, X., et al. (1998). Adenovirus mediated thymidine kinase gene therapy may enhance sensitivity of ovarian cancer cells to chemotherapeutic agents. Anticancer Res. 18: 3421-3426.
32. Kieback, D. G., et al. (2002). Intraperitoneal adenovirus-mediated suicide gene therapy in combination with either topotecan or paclitaxel in nude mice with human ovarian cancer. Cancer Gene Ther. 9: 478-481.
33. Ganly, I., et al. (2000). A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin. Cancer Res. 6: 798-806.
34. Khuri, F. R., et al. (2000). A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat. Med. 6: 879-885.
35. Gurnani, M., et al. (1999). Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer. Cancer Chemother. Pharmacol. 44: 143-151
36. Mizutani, Y., et al. (2001). Enhanced sensitivity of bladder cancer cells to tumor necrosis factor related apoptosis inducing ligand mediated apoptosis by cisplatin and carboplatin. J. Urol. 165: 263-270.
37. Elliott, M. J., et al. (2002). E2F-1 gene therapy induces apoptosis and increases chemosensitivity in human pancreatic carcinoma cells. Tumour Biol. 23: 76-86.
38. Tanaka, M., and Grossman, H. B. (2001). Connexin 26 gene therapy of human bladder cancer: induction of growth suppression, apoptosis, and synergy with cisplatin. Hum. Gene Ther. 12: 2225-2236.
39. Zhou, Z., Jia, S. F., Hung, M. C., Kleinerman, E. S. (2001). E1A sensitizes HER2/neu-overexpressing Ewing's sarcoma cells to topoisomerase II-targeting anticancer drugs. Cancer Res. 61: 3394-3398.